188 related articles for article (PubMed ID: 28170128)
41. Downregulation of IGF1R Expression Inhibits Growth and Enhances Cisplatin Sensitivity of Head and Neck Squamous Cell Carcinoma Cells In Vitro.
Khalil A; Jameson MJ
Horm Cancer; 2019 Feb; 10(1):11-23. PubMed ID: 30350263
[TBL] [Abstract][Full Text] [Related]
42. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
[TBL] [Abstract][Full Text] [Related]
43. Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines.
Affolter A; Samosny G; Heimes AS; Schneider J; Weichert W; Stenzinger A; Sommer K; Jensen A; Mayer A; Brenner W; Mann WJ; Brieger J
Head Neck; 2017 Apr; 39(4):623-632. PubMed ID: 28221700
[TBL] [Abstract][Full Text] [Related]
44. Differential effects of short-chain fatty acids on head and neck squamous carcinoma cells.
Krishna S; Brown N; Faller DV; Spanjaard RA
Laryngoscope; 2002 Apr; 112(4):645-50. PubMed ID: 12150517
[TBL] [Abstract][Full Text] [Related]
45. Combination of betulinic acid with cisplatin--different cytotoxic effects in two head and neck cancer cell lines.
Eder-Czembirek C; Czembirek C; Erovic BM; Selzer E; Turhani D; Vormittag L; Thurnher D
Oncol Rep; 2005 Sep; 14(3):667-71. PubMed ID: 16077972
[TBL] [Abstract][Full Text] [Related]
46. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
[TBL] [Abstract][Full Text] [Related]
47. Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation.
Oh SH; Whang YM; Min HY; Han SH; Kang JH; Song KH; Glisson BS; Kim YH; Lee HY
Int J Cancer; 2012 Nov; 131(10):2253-63. PubMed ID: 22362554
[TBL] [Abstract][Full Text] [Related]
48. Oxaliplatin-mediated inhibition of survivin increases sensitivity of head and neck squamous cell carcinoma cell lines to paclitaxel.
Khan Z; Khan N; Varma AK; Tiwari RP; Mouhamad S; Prasad GB; Bisen P
Curr Cancer Drug Targets; 2010 Nov; 10(7):660-9. PubMed ID: 20578991
[TBL] [Abstract][Full Text] [Related]
49. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
[TBL] [Abstract][Full Text] [Related]
50. Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
Zumsteg ZS; Morse N; Krigsfeld G; Gupta G; Higginson DS; Lee NY; Morris L; Ganly I; Shiao SL; Powell SN; Chung CH; Scaltriti M; Baselga J
Clin Cancer Res; 2016 Apr; 22(8):2009-19. PubMed ID: 26589432
[TBL] [Abstract][Full Text] [Related]
51. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
[TBL] [Abstract][Full Text] [Related]
52. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin.
Fetz V; Bier C; Habtemichael N; Schuon R; Schweitzer A; Kunkel M; Engels K; Kovács AF; Schneider S; Mann W; Stauber RH; Knauer SK
Int J Cancer; 2009 May; 124(9):2033-41. PubMed ID: 19130609
[TBL] [Abstract][Full Text] [Related]
53. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
54. Resveratrol synergistically enhances the effect of etoposide in HNSCC cell lines.
Heiduschka G; Bigenzahn J; Brunner M; Thurnher D
Acta Otolaryngol; 2014 Oct; 134(10):1071-8. PubMed ID: 25220729
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of BH3 mimetics as a combination therapy with irradiation in head and neck squamous cell carcinoma.
Korelin K; Oostveen M; Wahbi W; Ianevski F; Cavalcante B; Turunen L; Belevich I; Al-Samadi A; Salo T
Biomed Pharmacother; 2024 Jun; 175():116719. PubMed ID: 38749173
[TBL] [Abstract][Full Text] [Related]
56. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
[TBL] [Abstract][Full Text] [Related]
57. Fenretinide-induced apoptosis of human head and neck squamous carcinoma cell lines.
Scher RL; Saito W; Dodge RK; Richtsmeier WJ; Fine RL
Otolaryngol Head Neck Surg; 1998 Apr; 118(4):464-71. PubMed ID: 9560096
[TBL] [Abstract][Full Text] [Related]
58. The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines.
Schnoell J; Sparr C; Al-Gboore S; Haas M; Brkic FF; Kadletz-Wanke L; Heiduschka G; Jank BJ
Invest New Drugs; 2023 Dec; 41(6):842-850. PubMed ID: 37934325
[TBL] [Abstract][Full Text] [Related]
59. The antitumor drug F14512 enhances cisplatin and ionizing radiation effects in head and neck squamous carcinoma cell lines.
Mouawad F; Gros A; Rysman B; Bal-Mahieu C; Bertheau C; Horn S; Sarrazin T; Lartigau E; Chevalier D; Bailly C; Lansiaux A; Meignan S
Oral Oncol; 2014 Feb; 50(2):113-9. PubMed ID: 24290982
[TBL] [Abstract][Full Text] [Related]
60. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.
Pavón MA; Arroyo-Solera I; Téllez-Gabriel M; León X; Virós D; López M; Gallardo A; Céspedes MV; Casanova I; López-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
Oncotarget; 2015 Oct; 6(30):29016-33. PubMed ID: 26359694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
